Data updated: Jun 28, 2026
Migraine Clinical Trial Landscape
Migraine is being studied across 511 clinical trials registered since 2008, with 87 programs currently active. The competitive pipeline includes 39 active Phase 3 trials, 20 active Phase 2 trials, and 5 active Phase 1 trials.
Top industry sponsors include AbbVie, Pfizer, H. Lundbeck A/S.
Trial activity
87 active / 511 total since 2008
Active by phase 39 Ph3 / 194 20 Ph2 / 115 5 Ph1 / 70 23 Ph4 / 132
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
AbbVie 10 26 3
Pfizer 8 21 4
H. Lundbeck A/S 4 12 1
Ipsen 3 0 0
Eli Lilly 2 26 4
Merz Therapeutics GmbH 2 0 0
Amgen 1 20 2
Theranica 1 2 0
Kallyope Inc. 1 1 1
Sichuan Purity Pharmaceutical Technology Co., Ltd. 1 1 0
Upsher-Smith Laboratories 1 1 0
IntraBio Inc 1 0 0
Alasht Pharmed 1 0 0
Dr George Medvedev 1 0 0
Evommune, Inc. 1 0 0
How the field has grown
New-trial starts peaked in 2019 (42 registered); 2025 saw 29. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (138 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 27
2017 41
2018 23
2019 42
2020 35
2021 34
2022 33
2023 23
2024 24
2025 29
2026 16
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (15) 875
2017 (17) 311
2018 (8) 822
2019 (18) 503
2020 (16) 494
2021 (17) 440
2022 (16) 431
2023 (13) 524
2024 (5) 496
2025 (10) 435
2026 (3) 60
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT05711394 RECRUITING
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
AbbVie n=450
NCT05125302 RECRUITING
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie n=1,059
NCT06417775 RECRUITING
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie n=496
NCT04965675 RECRUITING
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
H. Lundbeck A/S n=285
NCT06810505 RECRUITING
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
AbbVie n=420
NCT06241313 ACTIVE NOT RECRUITING
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
AbbVie n=1,300
NCT05156398 RECRUITING
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Pfizer n=640
NCT06641466 RECRUITING
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Pfizer n=723
NCT04649242 RECRUITING
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer n=2,100
NCT06806293 ACTIVE NOT RECRUITING
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie n=468
NCT07018713 RECRUITING
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
Merz Therapeutics GmbH n=780
NCT07018700 RECRUITING
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
Merz Therapeutics GmbH n=990
NCT06616194 RECRUITING
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
Pfizer n=200
NCT04743141 RECRUITING
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Pfizer n=600
NCT06047457 ACTIVE NOT RECRUITING
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
Ipsen n=751
NCT06047444 ACTIVE NOT RECRUITING
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
Ipsen n=759
NCT05164172 RECRUITING
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
H. Lundbeck A/S n=600
NCT07496034 RECRUITING
Efficacy of Gou-Teng-San (GTS) in Patients With Episodic Migraine
Tsai, Chueh-Yi, MD n=40
NCT05897320 RECRUITING
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
H. Lundbeck A/S n=315
NCT04616326 ACTIVE NOT RECRUITING
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Eli Lilly and Company n=312
NCT03432286 ACTIVE NOT RECRUITING
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
Eli Lilly and Company n=533
NCT06904287 RECRUITING
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
Wake Forest University Health Sciences n=100
NCT03836040 ACTIVE NOT RECRUITING
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
Amgen n=457
NCT07147972 NOT YET RECRUITING
Comparative Study of Nutraceuticals vs. Conventional Prophylactic Therapy in the Management of Migraine
Fayoum University n=100
NCT05707949 ENROLLING BY INVITATION
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
AbbVie n=650
NCT04069897 ACTIVE NOT RECRUITING
Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Migraine
St. Olavs Hospital n=170
NCT05127954 ENROLLING BY INVITATION
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
AbbVie n=1,200
NCT07040813 RECRUITING
The Nordic Chronic Migraine Trial of CGRP Monoclonal Antibody and Onabotulinumtoxin A Dual Therapy Compared to CGRP mAbs Monotherapy
Oslo University Hospital n=450
NCT05748483 ACTIVE NOT RECRUITING
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
AbbVie n=545
NCT04151472 RECRUITING
Idebenone for the Preventive Treatment of Migraine
Second Affiliated Hospital, School of Medicine, Zhejiang University n=180
NCT05598723 RECRUITING
BOTOX® vs. XEOMIN® for Chronic Migraine
Naval Medical Center Camp Lejeune n=128
NCT06937385 NOT YET RECRUITING
0.5% Bupivacaine Lower Cervical Intramuscular Injection vs IV Medications for Headache Treatment
HCA Florida North Florida Hospital n=100
NCT04946734 ACTIVE NOT RECRUITING
Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine
Guangdong Provincial People's Hospital n=440
NCT05484349 RECRUITING
TIzanidine for the Preventive Treatment of Episodic MigrainE （TIME）
Second Affiliated Hospital, School of Medicine, Zhejiang University n=189
NCT05741775 RECRUITING
Physiotherapy Intervention for Migraine Symptoms
Universiti Tunku Abdul Rahman n=87
NCT06428838 NOT YET RECRUITING
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
Dr George Medvedev n=102
NCT07629635 NOT YET RECRUITING
Migraine Headaches Elimination With Patent Foramen Ovale-Directed Therapy
Columbia University n=32
NCT07645924 NOT YET RECRUITING
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc. n=1,800
NCT04396574 TERMINATED
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Eli Lilly and Company n=558
NCT04396236 TERMINATED
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Eli Lilly and Company n=851
NCT04530110 COMPLETED
A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
Teva Branded Pharmaceutical Products R&D LLC n=506
NCT04163185 COMPLETED
Initiating Early Control of Migraine Pain and Associated Symptoms
Axsome Therapeutics, Inc. n=302
NCT03832998 COMPLETED
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
Amgen n=284
NCT05810038 COMPLETED
A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.
Pfizer n=787
NCT04921384 COMPLETED
Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine
H. Lundbeck A/S n=981
NCT05064371 COMPLETED
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
H. Lundbeck A/S n=160
NCT06103734 WITHDRAWN
A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants
Pfizer
NCT04464707 COMPLETED
A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age
Teva Branded Pharmaceutical Products R&D, Inc. n=292
NCT04686136 COMPLETED
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
AbbVie n=596
NCT05028569 TERMINATED
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
AbbVie n=775
NCT05550207 COMPLETED
Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)
Axsome Therapeutics, Inc. n=100
NCT05458011 COMPLETED
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine
Teva Branded Pharmaceutical Products R&D, Inc. n=365
NCT05399485 COMPLETED
Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)
Pfizer n=496
NCT03867201 COMPLETED
Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients
Novartis Pharmaceuticals n=557
NCT04726592 TERMINATED
Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room
Assistance Publique - Hôpitaux de Paris n=323
NCT05989048 COMPLETED
A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults
Pfizer n=1,414
NCT04437433 COMPLETED
A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine
AbbVie n=186
NCT05641363 COMPLETED
Comparison of Ketorolac at Three Doses in Children With Acute Pain
Hamilton Health Sciences Corporation n=171
NCT04458857 COMPLETED
A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
Teva Branded Pharmaceutical Products R&D, Inc. n=235
NCT05216263 COMPLETED
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
AbbVie n=75
NCT02725554 WITHDRAWN
Study of Wireless Nerve Stimulation in the Treatment of Chronic Migraine
Curonix LLC
NCT04804033 TERMINATED
A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
Pfizer n=1,753
NCT05861427 COMPLETED
Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine
AbbVie n=524
NCT05102591 COMPLETED
A Pilot Clinical Trial of a New Neuromodulation Device for Acute Attacks of Migraine in Children and Adolescents
University of Calgary n=22
NCT05399459 COMPLETED
Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)
Pfizer n=897
NCT04989413 TERMINATED
Cannabidiol 133mg + Cannabigerol 66mg + Tetrahydrocannabinol 4mg Vs Placebo As Adjuvant Treatment in Chronic Migraine -
Hospital Israelita Albert Einstein n=110
NCT05371652 COMPLETED
A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants
Pfizer n=241
NCT04384367 COMPLETED
Efficacy and Safety of Rizatriptan-Naproxen (10/550 Mg) in the Acute Treatment of Migraine
Eurofarma Laboratorios S.A. n=2,068
NCT06004388 COMPLETED
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)
Click Therapeutics, Inc. n=110
NCT05967442 COMPLETED
Magnesium Versus Prochlorperazine Versus Metoclopramide for Migraines
Wake Forest University Health Sciences n=157
NCT03732638 COMPLETED
Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults
Pfizer n=1,590
NCT00812006 COMPLETED
A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis
Organon and Co n=108
NCT00894556 COMPLETED
A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)
Organon and Co n=109
NCT04698525 COMPLETED
Comparative Study Between Valproate and Memantine in the Prophylactic Management of Episodic Migraine.
Universidad Autonoma de San Luis Potosí n=33
NCT01001234 COMPLETED
A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)
Organon and Co n=1,382
NCT01004263 COMPLETED
A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)
Organon and Co n=674
NCT05632133 COMPLETED
The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients
Kafrelsheikh University n=200
NCT04349176 TERMINATED
Onabotulinum Dose Comparison in Chronic Migraine Superior to 100 Units?
United States Naval Medical Center, San Diego n=35
NCT03337620 COMPLETED
Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine
Tian Medical Inc. n=174
NCT04574362 COMPLETED
Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine
Pfizer n=1,648
NCT04940390 COMPLETED
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine
Satsuma Pharmaceuticals, Inc. n=1,591
NCT05046522 COMPLETED
A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.
RDC Clinical Pty Ltd n=80
NCT04068051 COMPLETED
Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)
Axsome Therapeutics, Inc. n=706
NCT04418765 COMPLETED
A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments
H. Lundbeck A/S n=892
NCT04740827 COMPLETED
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.
Allergan n=315
NCT03896009 COMPLETED
Maximizing Outcomes in Treating Acute Migraine
Axsome Therapeutics, Inc. n=1,594
NCT03338920 TERMINATED
Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents
Currax Pharmaceuticals n=159
NCT04406649 COMPLETED
A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
Satsuma Pharmaceuticals, Inc. n=482
NCT03901482 COMPLETED
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine
Satsuma Pharmaceuticals, Inc. n=1,201
NCT04492020 COMPLETED
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants
AbbVie n=518
NCT04829747 COMPLETED
Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine
Allergan n=3
NCT04408794 COMPLETED
Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine
Pfizer n=974
NCT03963232 COMPLETED
A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine
Eli Lilly and Company n=520
NCT03303105 COMPLETED
Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Otsuka Pharmaceutical Co., Ltd. n=50
NCT03235479 COMPLETED
Safety and Efficacy Study in Adult Subjects With Acute Migraines
Pfizer n=1,485
NCT03855137 COMPLETED
Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
Allergan n=778
NCT03009019 COMPLETED
Efficacy, Tolerability, and Safety of DFN-15
BioDelivery Sciences International n=631
NCT03006276 COMPLETED
Efficacy, Tolerability, and Safety Study of DFN-15
BioDelivery Sciences International n=622
NCT04772742 COMPLETED
Eptinezumab in Adults With Migraine and Medication Overuse Headache
H. Lundbeck A/S n=193
NCT02483585 COMPLETED
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention
Amgen n=577
NCT02456740 COMPLETED
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
Amgen n=955
NCT03670810 COMPLETED
A Study of Lasmiditan (LY573144) Over Four Migraine Attacks
Eli Lilly and Company n=1,633
NCT02614261 COMPLETED
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
Eli Lilly and Company n=1,117
NCT03939312 COMPLETED
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
Allergan n=685
NCT03096834 COMPLETED
A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies
Novartis Pharmaceuticals n=246
NCT02358681 COMPLETED
Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children
Columbia University n=59
NCT02621931 COMPLETED
Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine
Teva Branded Pharmaceutical Products R&D, Inc. n=1,130
NCT03308968 COMPLETED
An Efficacy and Safety Study of Fremanezumab in Adults With Migraine
Teva Branded Pharmaceutical Products R&D, Inc. n=838
NCT02629861 COMPLETED
Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine
Teva Branded Pharmaceutical Products R&D, Inc. n=875
NCT02638103 COMPLETED
Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine
Teva Branded Pharmaceutical Products R&D, Inc. n=1,890
NCT02447991 COMPLETED
Rizatriptan for Episodic Dizziness in Vestibular Migraine
Robert W. Baloh n=223
NCT04355117 COMPLETED
A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients
Otsuka Pharmaceutical Co., Ltd. n=71
NCT03333109 COMPLETED
Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients
Novartis Pharmaceuticals n=900
NCT04152083 COMPLETED
A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine
H. Lundbeck A/S n=485
NCT03303092 COMPLETED
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine
Otsuka Pharmaceutical Co., Ltd. n=357
NCT03777059 COMPLETED
12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine
Allergan n=910
NCT03700320 COMPLETED
Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
Allergan n=744
NCT03303079 COMPLETED
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine
Otsuka Pharmaceutical Co., Ltd. n=571
NCT03185143 COMPLETED
Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea
Allodynic Therapeutics, Inc n=36
NCT04218162 COMPLETED
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean
IlDong Pharmaceutical Co Ltd n=294
NCT03557333 COMPLETED
Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301)
Impel Pharmaceuticals n=360
NCT03275922 COMPLETED
Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE
Impax Laboratories, LLC n=374
NCT02959190 COMPLETED
A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine
Eli Lilly and Company n=311
NCT02565186 COMPLETED
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
Eli Lilly and Company n=2,171
NCT03282227 COMPLETED
A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine
Zosano Pharma Corporation n=342
NCT02665273 COMPLETED
Greater Occipital Nerve Block With Bupivacaine for Acute Migraine
Montefiore Medical Center n=28
NCT03559257 COMPLETED
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
Eli Lilly and Company n=463
NCT02614287 COMPLETED
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
Eli Lilly and Company n=270
NCT02614196 COMPLETED
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
Eli Lilly and Company n=986
NCT02614183 COMPLETED
Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study
Eli Lilly and Company n=862
NCT02974153 COMPLETED
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
Alder Biopharmaceuticals, Inc. n=1,121
NCT04114630 WITHDRAWN
Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab
Novartis Pharmaceuticals
NCT02559895 COMPLETED
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
Alder Biopharmaceuticals, Inc. n=898
NCT02985398 COMPLETED
An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine
Alder Biopharmaceuticals, Inc. n=128
NCT02439320 COMPLETED
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
Eli Lilly and Company n=2,231
NCT02794441 COMPLETED
Oral Dexamethasone for the Treatment of Acute Migraine Recurrence in the Pediatric Emergency Department
Children's Hospital of Eastern Ontario n=12
NCT02605174 COMPLETED
Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
Eli Lilly and Company n=3,005
NCT02873221 COMPLETED
An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
Allergan n=1,254
NCT02933060 COMPLETED
Intravenous Fluid Therapy for the Treatment of Emergency Department Patients With Migraine Headache
The Cooper Health System n=50
NCT02706015 WITHDRAWN
Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks
Ache Laboratorios Farmaceuticos S.A.
NCT02582996 SUSPENDED
Cefalium® Compared to Tylenol® in the Treatment of Migraine Attacks
Ache Laboratorios Farmaceuticos S.A. n=336
NCT02867709 COMPLETED
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Allergan n=1,686
NCT02828020 COMPLETED
Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
Allergan n=1,672
NCT01604785 COMPLETED
Low-dose Propofol for Pediatric Migraine
Oregon Health and Science University n=74
NCT02848326 COMPLETED
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
Allergan n=834
NCT01125774 COMPLETED
Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)
Merck Sharp & Dohme LLC n=4,548
NCT00662818 COMPLETED
Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)
Merck Sharp & Dohme LLC n=165
NCT00963937 COMPLETED
Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents
GlaxoSmithKline n=178
NCT02569853 COMPLETED
DFN-11 Injection in Episodic Migraine With or Without Aura
Dr. Reddy's Laboratories Limited n=268
NCT00682734 COMPLETED
Metoclopramide for Migraine: A Dose Finding Study
Montefiore Medical Center n=349
NCT02745392 COMPLETED
Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine
Zosano Pharma Corporation n=365
NCT02279082 COMPLETED
DFN-02 Open Label Safety Study in Patients With Acute Migraine
Dr. Reddy's Laboratories Limited n=167
NCT01662492 COMPLETED
A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine
Allergan n=125
NCT00557544 WITHDRAWN
Trial on Metoclopramide and Ketoprofen in Acute Migraine of Childhood
IRCCS Burlo Garofolo
NCT01581281 TERMINATED
The Childhood and Adolescent Migraine Prevention Study
Children's Hospital Medical Center, Cincinnati n=488
NCT03193346 WITHDRAWN
BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine
Allergan
NCT03193359 WITHDRAWN
Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine
Allergan
NCT01667679 COMPLETED
Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura
Avanir Pharmaceuticals n=275
NCT01390324 WITHDRAWN
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine
Ache Laboratorios Farmaceuticos S.A.
NCT01391091 COMPLETED
Effect of Catheter Ablation on Clinical Course of Migraine in AF Patients With or Without Previous History of Migraine
Texas Cardiac Arrhythmia Research Foundation n=173
NCT01016678 COMPLETED
Treximet Early Intervention Adolescent Migraine
Premiere Research Institute n=104
NCT01726920 WITHDRAWN
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine.
Ache Laboratorios Farmaceuticos S.A.
NCT00660192 COMPLETED
Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches
Yale University n=25
NCT00792103 COMPLETED
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
NuPathe Inc. n=198
NCT00806546 COMPLETED
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
NuPathe Inc. n=514
NCT00724815 COMPLETED
The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine
NuPathe Inc. n=530
NCT01357031 COMPLETED
Study With Amitriptylin to Evaluate the Efficacy of Melatonin in Treatment of Migraine
Hospital Israelita Albert Einstein n=192
NCT01695460 COMPLETED
A Randomized, Parallel, Double-blind, Placebo-controlled Study of Vitamin D as Prophylactic Treatment for Migraine
Aalborg University n=48
NCT01973205 COMPLETED
Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine
Novartis n=900
NCT02122237 COMPLETED
Cathodal tDCS in Chronic Migraine: Neurophysiological Study and Pilot Therapeutic Trial
University of Liege n=14
NCT01462812 COMPLETED
Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine
Optinose US Inc. n=223
NCT01151787 TERMINATED
Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine
Kennedy Medical Group n=35
NCT00884663 COMPLETED
Candesartan Versus Propranolol for Migraine Prevention
Norwegian University of Science and Technology n=72
NCT01814189 COMPLETED
Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment
Shahid Beheshti University of Medical Sciences n=350
NCT00573170 COMPLETED
TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults
GlaxoSmithKline n=375
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only